Literature DB >> 23929627

Dynamic expression profiling of type I and type III interferon-stimulated hepatocytes reveals a stable hierarchy of gene expression.

Christopher R Bolen1, Siyuan Ding, Michael D Robek, Steven H Kleinstein.   

Abstract

Despite activating similar signaling cascades, the type I and type III interferons (IFNs) differ in their ability to antagonize virus replication. However, it is not clear whether these cytokines induce unique antiviral states, particularly in the liver, where the clinically important hepatitis B and C viruses cause persistent infection. Here, clustering and promoter analyses of microarray-based gene expression profiling were combined with mechanistic studies of signaling pathways to dynamically characterize the transcriptional responses induced by these cytokines in Huh7 hepatoma cells and primary human hepatocytes. Type I and III IFNs differed greatly in their level of interferon-stimulated gene (ISG) induction with a clearly detectable hierarchy (IFN-β > IFN-α > IFN-λ3 > IFN-λ1 > IFN-λ2). Notably, although the hierarchy identified varying numbers of differentially expressed genes when quantified using common statistical thresholds, further analysis of gene expression over multiple timepoints indicated that the individual IFNs do not in fact regulate unique sets of genes. The kinetic profiles of IFN-induced gene expression were also qualitatively similar with the important exception of IFN-α. While stimulation with either IFN-β or IFN-λs resulted in a similar long-lasting ISG induction, IFN-α signaling peaked early after stimulation then declined due to a negative feedback mechanism. The quantitative expression hierarchy and unique kinetics of IFN-α reveal potential specific roles for individual IFNs in the immune response, and elucidate the mechanism behind previously observed differences in IFN antiviral activity. While current clinical trials are focused on IFN-λ1 as a potential antiviral therapy, the finding that IFN-λ3 invariably possesses the highest activity among type III IFNs suggests that this cytokine may have superior clinical activity.
© 2014 by the American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 23929627      PMCID: PMC3938553          DOI: 10.1002/hep.26657

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  32 in total

1.  Protein kinase C-delta (PKC-delta ) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727.

Authors:  Shahab Uddin; Antonella Sassano; Dilip K Deb; Amit Verma; Beata Majchrzak; Arshad Rahman; Asrar B Malik; Eleanor N Fish; Leonidas C Platanias
Journal:  J Biol Chem       Date:  2002-02-11       Impact factor: 5.157

2.  IL-28, IL-29 and their class II cytokine receptor IL-28R.

Authors:  Paul Sheppard; Wayne Kindsvogel; Wenfeng Xu; Katherine Henderson; Stacy Schlutsmeyer; Theodore E Whitmore; Rolf Kuestner; Ursula Garrigues; Carl Birks; Jenny Roraback; Craig Ostrander; Dennis Dong; Jinu Shin; Scott Presnell; Brian Fox; Betty Haldeman; Emily Cooper; David Taft; Teresa Gilbert; Francis J Grant; Monica Tackett; William Krivan; Gary McKnight; Chris Clegg; Don Foster; Kevin M Klucher
Journal:  Nat Immunol       Date:  2002-12-02       Impact factor: 25.606

3.  Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation.

Authors:  Z Wen; Z Zhong; J E Darnell
Journal:  Cell       Date:  1995-07-28       Impact factor: 41.582

4.  USP18 establishes the transcriptional and anti-proliferative interferon α/β differential.

Authors:  Véronique Francois-Newton; Mark Livingstone; Béatrice Payelle-Brogard; Gilles Uzé; Sandra Pellegrini
Journal:  Biochem J       Date:  2012-09-15       Impact factor: 3.857

5.  Lambda and alpha interferons inhibit hepatitis B virus replication through a common molecular mechanism but with different in vivo activities.

Authors:  Nicole E Pagliaccetti; Esther N Chu; Christopher R Bolen; Steven H Kleinstein; Michael D Robek
Journal:  Virology       Date:  2010-03-29       Impact factor: 3.616

6.  Transcription factor redundancy ensures induction of the antiviral state.

Authors:  Sonja Schmid; Markus Mordstein; Georg Kochs; Adolfo García-Sastre; Benjamin R Tenoever
Journal:  J Biol Chem       Date:  2010-10-13       Impact factor: 5.157

7.  Human interferon-lambda3 is a potent member of the type III interferon family.

Authors:  C Dellgren; H H Gad; O J Hamming; J Melchjorsen; R Hartmann
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

8.  Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2.

Authors:  Zrinka Marijanovic; Josiane Ragimbeau; José van der Heyden; Gilles Uzé; Sandra Pellegrini
Journal:  Biochem J       Date:  2007-10-01       Impact factor: 3.857

9.  IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy.

Authors:  Vijayaprakash Suppiah; Max Moldovan; Golo Ahlenstiel; Thomas Berg; Martin Weltman; Maria Lorena Abate; Margaret Bassendine; Ulrich Spengler; Gregory J Dore; Elizabeth Powell; Stephen Riordan; David Sheridan; Antonina Smedile; Vincenzo Fragomeli; Tobias Müller; Melanie Bahlo; Graeme J Stewart; David R Booth; Jacob George
Journal:  Nat Genet       Date:  2009-09-13       Impact factor: 38.330

10.  Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction.

Authors:  Henning Schulze-Bergkamen; Binje Fleischer; Marcus Schuchmann; Achim Weber; Arndt Weinmann; Peter H Krammer; Peter R Galle
Journal:  BMC Cancer       Date:  2006-10-02       Impact factor: 4.430

View more
  96 in total

Review 1.  Innate Immune Signaling Activated by MDR Bacteria in the Airway.

Authors:  Dane Parker; Danielle Ahn; Taylor Cohen; Alice Prince
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

Review 2.  Type III Interferons in Antiviral Defenses at Barrier Surfaces.

Authors:  Alexandra I Wells; Carolyn B Coyne
Journal:  Trends Immunol       Date:  2018-09-12       Impact factor: 16.687

3.  Respiratory syncytial virus infection induces a subset of types I and III interferons in human dendritic cells.

Authors:  Philippa Hillyer; Viraj P Mane; Aaron Chen; Maria B Dos Santos; Lynnsie M Schramm; Rachel E Shepard; Cindy Luongo; Cyril Le Nouën; Lei Huang; Lihan Yan; Ursula J Buchholz; Ronald G Jubin; Peter L Collins; Ronald L Rabin
Journal:  Virology       Date:  2017-01-31       Impact factor: 3.616

4.  Profiling of rotavirus 3'UTR-binding proteins reveals the ATP synthase subunit ATP5B as a host factor that supports late-stage virus replication.

Authors:  Lili Ren; Siyuan Ding; Yanhua Song; Bin Li; Muthukumar Ramanathan; Julia Co; Manuel R Amieva; Paul A Khavari; Harry B Greenberg
Journal:  J Biol Chem       Date:  2019-02-15       Impact factor: 5.157

5.  Impact of Type I and III Interferons on Respiratory Superinfections Due to Multidrug-Resistant Pathogens.

Authors:  Dane Parker
Journal:  J Infect Dis       Date:  2017-02-15       Impact factor: 5.226

Review 6.  Contribution of type III interferons to antiviral immunity: location, location, location.

Authors:  Sergei V Kotenko; Joan E Durbin
Journal:  J Biol Chem       Date:  2017-03-13       Impact factor: 5.157

Review 7.  Interferon-stimulated genes: a complex web of host defenses.

Authors:  William M Schneider; Meike Dittmann Chevillotte; Charles M Rice
Journal:  Annu Rev Immunol       Date:  2014-02-06       Impact factor: 28.527

8.  Butyrate Reprograms Expression of Specific Interferon-Stimulated Genes.

Authors:  Mahesh Chemudupati; Adam D Kenney; Anna C Smith; Robert J Fillinger; Lizhi Zhang; Ashley Zani; Shan-Lu Liu; Matthew Z Anderson; Amit Sharma; Jacob S Yount
Journal:  J Virol       Date:  2020-07-30       Impact factor: 5.103

9.  SOCS1 is an inducible negative regulator of interferon λ (IFN-λ)-induced gene expression in vivo.

Authors:  Tanja Blumer; Mairene Coto-Llerena; Francois H T Duong; Markus H Heim
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

10.  Outcomes of Congenital Zika Disease Depend on Timing of Infection and Maternal-Fetal Interferon Action.

Authors:  Jinling Chen; Yuejin Liang; Panpan Yi; Lanman Xu; Hal K Hawkins; Shannan L Rossi; Lynn Soong; Jiyang Cai; Ramkumar Menon; Jiaren Sun
Journal:  Cell Rep       Date:  2017-11-07       Impact factor: 9.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.